Search clinical trials for: Egg-based Quadrivalent Influenza Vaccine

Total 1283 results

Dalhousie University
GlaxoSmithKline; Canadian Institutes of Health Research (CIHR); IWK Health Centre

Completed

Evaluation of Seasonal Influenza Vaccine for 2010-2011 in Young Children

Seasonal Influenza

Canada
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
University of Colorado, Denver
Colorado Clinical & Translational Sciences Institute

Completed

Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults

Rheumatologic Disorder | Dialysis | Human Immunodeficiency Virus (HIV) | Solid Organ Transplant Recipient (Liver, Kidney, Heart) | Bone Marrow Transplant (BMT)

United States
National Institute of Allergy and Infectious Diseases...

Completed

Trivalent Baculovirus-expressed Influenza HA Vaccine in Adults With Non-Hodgkin's B-cell Lymphoma

Influenza

United States
University of Pittsburgh
Sanofi Pasteur, a Sanofi Company

Completed

Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting

Influenza

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

Pandemic H5N1 Influenza

Poland, Turkey
Center for Disease Prevention and Control of Beijing...

Completed

Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military

Influenza

China
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

Influenza | Flu

United States
Novavax
Department of Health and Human Services

Completed

A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults

Influenza

Australia
Green Cross Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

Influenza Infection
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

Influenza

United States
Butantan Institute

Completed

Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine - FLU-02-IB (FLU-02-IB)

Influenza

Brazil
National Institute of Allergy and Infectious Diseases...

Withdrawn

High Dose Influenza in Immunosuppressed Subjects

Influenza

United States
Novartis
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

Pandemic Influenza Disease

Finland, Germany
Novartis Vaccines

Completed

Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects

Swine-Origin Influenza A H1N1 Virus

Japan
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

HIV Infections | Influenza

United States, Puerto Rico
MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
Novartis Vaccines

Completed

Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects

Influenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza Virus

Belgium
Nova Immunotherapeutics Limited
The Emmes Company, LLC; Nova Laboratories Limited; Mercia Pharma Inc.

Unknown

The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) (MER4101)

Influenza, Human

United States
GlaxoSmithKline

Completed

Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children

Influenza

Spain
Sinovac Biotech Co., Ltd

Completed

Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults

Influenza

China
Chiltern Pesquisa Clinica Ltda

Completed

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors

H1N1 Influenza Virus | Invasive Solid Tumors

Brazil
Butantan Institute

Completed

Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine

Influenza

Brazil
The University of Hong Kong
Centers for Disease Control and Prevention; Hospital Authority, Hong Kong

Active, not recruiting

Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong (RETAIN)

Influenza, Human

China
Institute of Medical Biology, Chinese Academy of...
Hebei Center for Disease Control and Prevention

Completed

The Clinical Trial Protocol for the Influenza Virus Vaccine (Split Virion, Inactivated) （Children Forms of Drug）

Influenza

China
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
Queen Saovabha Memorial Institute

Completed

Two-site Intradermal Influenza Vaccination in Elderly

Influenza

Thailand
Patricia L. Hibberd

Completed

Safety of Lactobacillus Rhamnosus GG Versus Placebo in Elderly Subjects Receiving Live Attenuated Influenza Vaccine (LAIV)

Healthy | Influenza

United States
Jiangsu Province Centers for Disease Control and...

Completed

Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine

COVID-19

China
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Auto-immunity in Lupus Patients After Influenza Vaccine (GRIPLUP)

Systemic Lupus Erythematosus (SLE)

France
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)

Influenza

United States
Seqirus
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above

Influenza

Germany
Bill & Melinda Gates Medical Research Institute
Iqvia Pty Ltd

Withdrawn

Proof of Concept Trial of Adjuvant Activity of SWE, a Squalene-based -Oil-in-water Emulsion

Influenza
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
Novartis
Novartis Vaccines

Completed

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

Meningococcal Meningitis

United States, Italy
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)

Influenza

United States
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

Influenza | SARS-CoV-2

United States
Mahidol University
Ministry of Health, Thailand; Bhumirajanagarindra Kidney Institute, Thailand

Completed

Immune Response to Influenza Vaccine in ESRD Patients

Immunology | Nephrology
International Centre for Diarrhoeal Disease Research...
Centers for Disease Control and Prevention; Institute of Epidemiology, Disease... and other collaborators

Recruiting

Influenza Vaccine Uptake Among Healthcare Workers

Influenza Vaccines

Bangladesh
VA Pharma Limited Liability Company

Unknown

Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu

Safety Issues

Russian Federation
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

Central Nervous System Neoplasm

United States
Adimmune Corporation

Completed

Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects

Influenza

Taiwan
Wayne Sullender, M.D.
All India Institute of Medical Sciences, New Delhi; Centers for Disease Control...

Completed

Direct and Indirect Protection by Influenza Vaccine Given to Children in India

Influenza

India
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Influenza

United States
University of Wisconsin, Madison

Completed

Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients

Inflammatory Bowel Disease (IBD)

United States
Stanford University
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)

MELAS Syndrome

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza Vaccines

Influenza | Myxovirus Infection | Orthomyxovirus Infections

France
Crucell Holland BV

Completed

Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different Suppliers

Influenza

Switzerland
National Centre for Epidemiology, Hungary
Netherlands Vaccine Institute; National Public Health Institute, Finland

Unknown

Comparison of the Cellular and the Humoral Immunogenicity, Safety of Different Trivalent Influenza Vaccines (FLUSECUOEKH1)

Healthy Volunteers

Hungary
St. Petersburg Research Institute of Vaccines and...

Completed

Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA

Influenza

Russian Federation

3

Subscribe